imatinib mesylate has been researched along with Menopause in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jönsson, S; Mellström, D; Olsson, B; Standal, T; Wadenvik, H | 1 |
1 trial(s) available for imatinib mesylate and Menopause
| Article | Year |
|---|---|
Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Benzamides; Biomarkers; Bone Density; Calcium; Collagen Type I; Female; Humans; Hyperparathyroidism, Secondary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnesium; Male; Menopause; Middle Aged; Osteocalcin; Parathyroid Hormone; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Smoking | 2012 |